

**Composition :** Betamethasone (as 17-valerate) 0.1% and Neomycin sulphate 0.5%.

**Indications :** **Betavate-N** preparations are indicated for the treatment of the following conditions where secondary bacterial infection is present, suspected, or likely to occur: eczema in children and adults, including atopic and discoid eczema, prurigo nodularis; psoriasis (excluding widespread plaque psoriasis). neurodermatoses, seborrhoeic dermatitis, contact sensitivity reactions and it may be used as an adjunct to systemic steroid therapy in generalised erythroderma. This preparation can also be used in the management of secondarily infected insect bites and anal and genital intertrigo.

**Dosage and administration :** Apply to the affected area once or twice daily until improvement occurs. Therapy should be discontinued when control is achieved. Or as directed by the registered physician.

**Contraindication :** Rosacea, acne vulgaris and peri-oral dermatitis. Primary cutaneous viral infections (e. g. herpes simplex, chickenpox). Hypersensitivity to any components of the drug.

**Pregnancy and lactation :** There is inadequate evidence of safety in human pregnancy. Pregnancy Category of

## Betavate-N Cream

Betamethasone-**C** & Neomycin-**D**.

**Side effects :** Signs of hypersensitivity may appear. Prolonged and intensive treatment with highly active corticosteroid preparations may cause local atrophic changes in the skin such as thinning, stria, and dilatation of the superficial blood vessels, particularly when occlusive dressings are used or when skin folds are involved.

**Precautions :** Long-term continuous topical therapy should be avoided where possible, particularly in infants and children, as adrenal suppression can occur even without occlusion. If used in childhood, or on the face, courses should be limited to five days.

**Packing :** **Betavate-N Cream:** 10 gram in a tube.